SEATTLE (October 13, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop immunotherapeutics and preventive vaccines, announced today that novel data from a preclinical study of its HIV vaccine was published in Vaccine, in a paper entitled, “Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.”
Etubics compared the immune response induced by the Etubics Platform (Ad5[E1-, E2b-]) by first
immunizing non-human primates (NHP) against adenovirus (Ad), the basis of the Etubics Platform. The NHP were then immunized with an Etubics Platform Vaccine targeting the monkey form of HIV, called SIV. Etubics HIV vaccine targets gag and nef and was able to induce a robust immune response. Next, the NHP were immunized against the HIV target Pol which resulted in an immune induction against the third HIV vaccine target, overcoming a vector immune response. Together, this data shows that the Etubics Platform can induce a robust cell mediated immune (CMI) response against multiple antigens in the presence of vector-specific immune responses, thus breaking the barrier of Ad5 immunity. These CMI responses increased over a course of multiple immunizations and the response profiles observed in Ad5 naïve and Ad5 immune NHP were similar. This data indicate that Etubics Platform vaccines could be used for vaccination regimes to induce heightened CMI responses in the presence of Ad5 immunity.
In a similar NHP model, it was reported that the CMI response induced by an earlier generation
Ad5 [E1-] vector were significantly affected by pre-exposure to Ad5. The mitigating effect of pre existing Ad5 immunity when vaccinating with Ad5 [E1-] platforms has also been reported in human immunogenicity studies.
Etubics has overcome the issue of Ad5 immunity through reducing the expression of viral vector
proteins by removing extensive genetic regions of the viral backbone. Reduced expression of Ad5 viral genes in a recombinant vector platform is advantageous in vaccine development because: it reduces antigenic competition between the target and Ad5 proteins; provides greater longevity of target transgene expression creating a larger immunologic stimulus; and decreases adverse effects, allowing for higher and more frequent doses of vaccine.
Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics stated, “We are
excited to show that our Etubics Platform can be utilized to not only overcome Ad5 immunity, which has plagued researchers in the past, but that it can be used to immunize against one target and then come back and successfully immunize against another disease target. We believe that this is a key difference from past generation Ad5 vaccines and our Etubics Platform vaccines .”
Etubics pre-clinical HIV work has been fully funded through grants from the National Institute of
Allergy and Infectious Diseases (NIAID). To view the paper online, visit Vaccine’s ScienceDirect.
Etubics is developing the next generation in vaccines and immunotherapies, utilizing a patented
advanced generation adenovirus delivery platform and a validated manufacturing human cell line,
collectively the Etubics Platform. Etubics has completed a Phase I/IIa clinical trial with an
immunotherapeutic product candidate to treat colorectal cancer. Etubics Phase I/IIa colorectal cancer trial has been funded primarily through grants from the National Cancer Institute (NCI). The NCI also awarded earlier grants to Etubics for its colorectal and breast cancer pre-clinical and colorectal clinical work.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 email@example.com